Targeting the CXCR4 Pathway Using a Novel Anti-CXCR4 IgG1 Antibody (PF-06747143) in Chronic Lymphocytic Leukemia

Overview

Journal J Hematol Oncol

Publisher Biomed Central

Specialties Hematology
Oncology

Date 2017 May 21

PMID 28526063

Citations 33

Authors

Manoj K Kashyap

Carlos I Amaya-Chanaga

Deepak Kumar

Brett Simmons

Nanni Huser

Yin Gu

Max Hallin

Kevin Lindquist

Rolla Yafawi

Michael Y Choi

Ale-Ali Amine

Laura Z Rassenti

Cathy Zhang

Shu-Hui Liu

Tod Smeal

Valeria R Fantin

Thomas J Kipps

Flavia Pernasetti

Januario E Castro

Affiliations

Soon will be listed here.

Abstract

Background: The CXCR4-CXCL12 axis plays an important role in the chronic lymphocytic leukemia (CLL)-microenvironment interaction. Overexpression of CXCR4 has been reported in different hematological malignancies including CLL. Binding of the pro-survival chemokine CXCL12 with its cognate receptor CXCR4 induces cell migration. CXCL12/CXCR4 signaling axis promotes cell survival and proliferation and may contribute to the tropism of leukemia cells towards lymphoid tissues and bone marrow. Therefore, we hypothesized that targeting CXCR4 with an IgG1 antibody, PF-06747143, may constitute an effective therapeutic approach for CLL.

Methods: Patient-derived primary CLL-B cells were assessed for cytotoxicity in an in vitro model of CLL microenvironment. PF-06747143 was analyzed for cell death induction and for its potential to interfere with the chemokine CXCL12-induced mechanisms, including migration and F-actin polymerization. PF-06747143 in vivo efficacy was determined in a CLL murine xenograft tumor model.

Results: PF-06747143, a novel-humanized IgG1 CXCR4 antagonist antibody, induced cell death of patient-derived primary CLL-B cells, in presence or absence of stromal cells. Moreover, cell death induction by the antibody was independent of CLL high-risk prognostic markers. The cell death mechanism was dependent on CXCR4 expression, required antibody bivalency, involved reactive oxygen species production, and did not require caspase activation, all characteristics reminiscent of programmed cell death (PCD). PF-06747143 also induced potent B-CLL cytotoxicity via Fc-driven antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity activity (CDC). PF-06747143 had significant combinatorial effect with standard of care (SOC) agents in B-CLL treatment, including rituximab, fludarabine (F-ara-A), ibrutinib, and bendamustine. In a CLL xenograft model, PF-06747143 decreased tumor burden and improved survival as a monotherapy, and in combination with bendamustine.

Conclusions: We show evidence that PF-06747143 has biological activity in CLL primary cells, supporting a rationale for evaluation of PF-06747143 for the treatment of CLL patients.

Citing Articles

Tumor microenvironment as a novel therapeutic target for lymphoid leukemias.

Mousavi S, Nouri S, Sadeghipour A, Atashi A Ann Hematol. 2025; .

PMID: 39994019 DOI: 10.1007/s00277-025-06237-w.

Proliferating CLL cells express high levels of CXCR4 and CD5.

Friedman D, Mehtani D, Vidler J, Patten P, Hoogeboom R Hemasphere. 2024; 8(12):e70064.

PMID: 39691453 PMC: 11651208. DOI: 10.1002/hem3.70064.

Artificial blood-hope and the challenges to combat tumor hypoxia for anti-cancer therapy.

Sharma R, Kashyap M, Zayed H, Krishnia L, Kashyap M Med Biol Eng Comput. 2024; .

PMID: 39614063 DOI: 10.1007/s11517-024-03233-6.

Structural insights into CXCR4 modulation and oligomerization.

Saotome K, McGoldrick L, Ho J, Ramlall T, Shah S, Moore M Nat Struct Mol Biol. 2024; 32(2):315-325.

PMID: 39313635 PMC: 11832422. DOI: 10.1038/s41594-024-01397-1.

Tuning the B-CLL microenvironment: evidence for BAG3 protein- mediated regulation of stromal fibroblasts activity.

Basile A, Giudice V, Mettivier L, Falco A, Cammarota A, DArdia A Cell Death Discov. 2024; 10(1):383.

PMID: 39198407 PMC: 11358476. DOI: 10.1038/s41420-024-02153-6.

References

Kashyap M, Kumar D, Jones H, Amaya-Chanaga C, Choi M, Melo-Cardenas J . Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway. Oncotarget. 2015; 7(3):2809-22. PMC: 4823073. DOI: 10.18632/oncotarget.6465. View

Ten Hacken E, Burger J . Microenvironment dependency in Chronic Lymphocytic Leukemia: The basis for new targeted therapies. Pharmacol Ther. 2014; 144(3):338-48. DOI: 10.1016/j.pharmthera.2014.07.003. View

Burger M, Hartmann T, Krome M, Rawluk J, Tamamura H, Fujii N . Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells. Blood. 2005; 106(5):1824-30. DOI: 10.1182/blood-2004-12-4918. View

Egger L, Schneider J, Rheme C, Tapernoux M, Hacki J, Borner C . Serine proteases mediate apoptosis-like cell death and phagocytosis under caspase-inhibiting conditions. Cell Death Differ. 2003; 10(10):1188-203. DOI: 10.1038/sj.cdd.4401288. View

Honeychurch J, Alduaij W, Azizyan M, Cheadle E, Pelicano H, Ivanov A . Antibody-induced nonapoptotic cell death in human lymphoma and leukemia cells is mediated through a novel reactive oxygen species-dependent pathway. Blood. 2012; 119(15):3523-33. PMC: 5944831. DOI: 10.1182/blood-2011-12-395541. View

Li H, Wu C, Chen T, Zhang G, Zhao H, Ke C . Construction and characterization of an anti-CD20 mAb nanocomb with exceptionally excellent lymphoma-suppressing activity. Int J Nanomedicine. 2015; 10:4783-96. PMC: 4525799. DOI: 10.2147/IJN.S80129. View

Fleury C, Mignotte B, Vayssiere J . Mitochondrial reactive oxygen species in cell death signaling. Biochimie. 2002; 84(2-3):131-41. DOI: 10.1016/s0300-9084(02)01369-x. View

Balkwill F . The significance of cancer cell expression of the chemokine receptor CXCR4. Semin Cancer Biol. 2004; 14(3):171-9. DOI: 10.1016/j.semcancer.2003.10.003. View

Chatterjee S, Azad B, Nimmagadda S . The intricate role of CXCR4 in cancer. Adv Cancer Res. 2014; 124:31-82. PMC: 4322894. DOI: 10.1016/B978-0-12-411638-2.00002-1. View

10.

Veliz M, Pinilla-Ibarz J . Treatment of relapsed or refractory chronic lymphocytic leukemia. Cancer Control. 2011; 19(1):37-53. DOI: 10.1177/107327481201900105. View

11.

Bagacean C, Zdrenghea M, Tempescul A, Cristea V, Renaudineau Y . Anti-CD20 monoclonal antibodies in chronic lymphocytic leukemia: from uncertainties to promises. Immunotherapy. 2016; 8(5):569-81. DOI: 10.2217/imt-2015-0015. View

12.

Zheng J, Tan H, Matsudaira P, Choo A . Excess reactive oxygen species production mediates monoclonal antibody-induced human embryonic stem cell death via oncosis. Cell Death Differ. 2017; 24(3):546-558. PMC: 5344215. DOI: 10.1038/cdd.2016.164. View

13.

Stamatopoulos B, Meuleman N, De Bruyn C, Pieters K, Mineur P, Le Roy C . AMD3100 disrupts the cross-talk between chronic lymphocytic leukemia cells and a mesenchymal stromal or nurse-like cell-based microenvironment: pre-clinical evidence for its association with chronic lymphocytic leukemia treatments. Haematologica. 2011; 97(4):608-15. PMC: 3347654. DOI: 10.3324/haematol.2011.052779. View

14.

Panayiotidis P, Jones D, Ganeshaguru K, Foroni L, Hoffbrand A . Human bone marrow stromal cells prevent apoptosis and support the survival of chronic lymphocytic leukaemia cells in vitro. Br J Haematol. 1996; 92(1):97-103. DOI: 10.1046/j.1365-2141.1996.00305.x. View

15.

Burger J, Burkle A . The CXCR4 chemokine receptor in acute and chronic leukaemia: a marrow homing receptor and potential therapeutic target. Br J Haematol. 2007; 137(4):288-96. DOI: 10.1111/j.1365-2141.2007.06590.x. View

16.

Redman J, Hill E, AlDeghaither D, Weiner L . Mechanisms of action of therapeutic antibodies for cancer. Mol Immunol. 2015; 67(2 Pt A):28-45. PMC: 4529810. DOI: 10.1016/j.molimm.2015.04.002. View

17.

Peng S, Zhang X, Paul D, Kays L, Ye M, Vaillancourt P . Inhibition of CXCR4 by LY2624587, a Fully Humanized Anti-CXCR4 Antibody Induces Apoptosis of Hematologic Malignancies. PLoS One. 2016; 11(3):e0150585. PMC: 4782998. DOI: 10.1371/journal.pone.0150585. View

18.

Kuhne M, Mulvey T, Belanger B, Chen S, Pan C, Chong C . BMS-936564/MDX-1338: a fully human anti-CXCR4 antibody induces apoptosis in vitro and shows antitumor activity in vivo in hematologic malignancies. Clin Cancer Res. 2012; 19(2):357-66. DOI: 10.1158/1078-0432.CCR-12-2333. View

19.

Chiorazzi N, Rai K, Ferrarini M . Chronic lymphocytic leukemia. N Engl J Med. 2005; 352(8):804-15. DOI: 10.1056/NEJMra041720. View

20.

Mone A, Huang P, Pelicano H, Cheney C, Green J, Tso J . Hu1D10 induces apoptosis concurrent with activation of the AKT survival pathway in human chronic lymphocytic leukemia cells. Blood. 2003; 103(5):1846-54. DOI: 10.1182/blood-2003-08-2836. View